- Biotech stocks are making a comeback in May after a slump in April, with the industry group having a Relative Strength Rating of 86.
- Key biotech stocks to watch include Neurocrine Biosciences, United Therapeutics, CervoMed, Gyre Therapeutics, and Halozyme Therapeutics.
- These companies are making strides in areas such as neuroscience, chronic diseases, neurodegenerative diseases, liver fibrosis, and drug delivery.
Explore the latest developments in the biotech sector, with a focus on key stocks making strides in neuroscience, chronic diseases, neurodegenerative diseases, liver fibrosis, and drug delivery.
Neurocrine Biosciences: Leading in Neuroscience
Neurocrine Biosciences continues to dominate the biotech sector as a leader in the neuroscience space. The company recently sought FDA approval for crinecerfont, a treatment for congenital adrenal hyperplasia. Neurocrine is also testing treatments for schizophrenia and cognitive impairment tied to schizophrenia, with midstage test results expected in the third quarter.
United Therapeutics: Focusing on Chronic Diseases
United Therapeutics is making waves with its treatments for chronic diseases. The company’s drug, Tyvaso, a treatment for pulmonary arterial hypertension, saw a 56% surge in sales in the March quarter. United Therapeutics is also working on a pipeline of treatments, with results of a final-phase PAH study expected in 2026.
CervoMed: Tackling Neurodegenerative Diseases
CervoMed, previously known as EIP Pharma, is a clinical-stage biotech company working on treatments for neurodegenerative diseases. The company’s leading drug is in testing for patients with dementias, including Lewy body dementia and Alzheimer’s disease.
Gyre Therapeutics: Addressing Liver Fibrosis
Gyre Therapeutics is working on a drug to treat liver fibrosis due to hepatitis B and metabolic dysfunction-associated steatohepatitis. The company is also considering treatments for chronic obstructive pulmonary disease and pulmonary arterial hypertension.
Halozyme Therapeutics: Expert in Drug Delivery
Halozyme Therapeutics is known for its Enhanze technology, which helps deliver drugs under the skin via a subcutaneous injection. The technology is behind some of the biggest medicines on the market, including Johnson & Johnson’s Darzalex Faspro and Roche’s Herceptin.
Conclusion
The biotech sector is showing signs of recovery, with key stocks making significant strides in various areas. Investors should keep an eye on these companies as they continue to innovate and push the boundaries in their respective fields.
